methyl-jasmonate and Weight-Gain

Phytotherapy is becoming a treatment option in management of diseases including benign prostatic hyperplasia (BPH). We have shown previously that methyl jasmonate (MeJA) ameliorated BPH, however the underlying mechanism of action remains unknown. This study was designed to investigate in mechanistic terms the protective role of MeJA in BPH.. BPH was induced by daily injections of testosterone propionate (TP) (3mg/kg) for 28 days.. The weight and organo-somatic weight of prostate in BPH rats were 6.8 and 5.1 times higher than castrated-control group, respectively. Inflammatory markers; prostatic myeloperoxidase and total nitric oxide were significantly increased in BPH group. The activity of aniline hydroxylase (Phase I drug metabolizing enzyme) was significantly increased in BPH rats by 22%. In BPH group, immuno-histochemistry revealed strong expression of prostatic inducible nitric oxide synthase, cyclooxygenase-2 and Bcl. MeJA protects against TP-induced BPH via mechanisms that involve anti-inflammation, induction of apoptosis and inhibition of phase I drug metabolizing enzyme.

Topics: Acetates; Animals; Apoptosis; Biomarkers; Cyclopentanes; Finasteride; Inflammation; Lipids; Male; Metabolic Detoxication, Phase I; Nitric Oxide; Organ Size; Oxylipins; Prostate; Prostatic Hyperplasia; Rats, Wistar; Testosterone; Weight Gain